This article has been updated from a previous version to include comments from Trovagene's Q3 earnings call.

NEW YORK (GenomeWeb) – Trovagene reported after the close of the market on Monday flat year-over-year third quarter revenues as it trimmed its net loss in half.

For the three months ended Sept. 30, 2015, the San Diego-based molecular diagnostics developer reported $57,000 in revenues. The company reported $51,000 in royalty revenue compared to $57,000 a year ago, and $6,000 in diagnostic service revenue compared to none in Q3 2014.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.